Burchert A, Nicolini FE, le Coutre P, Saussele S, et al. Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX). Leukemia 2026 Jan 12. doi: 10.1038/s41375-025-02859.
PMID: 41526617